Show simple item record

dc.contributor.authorZampi, Maddalena
dc.contributor.authorMorabito, Antonietta
dc.contributor.authorSalvato, Fabiana
dc.contributor.authorVinciguerra, Annamaria
dc.date.accessioned2013-05-28T14:14:00Z
dc.date.available2013-05-28T14:14:00Z
dc.date.issued2012
dc.identifier.citationZampi M, Morabito A, Salvato F, Vinciguerra A. Breakthrough pain: the importance of baseline analgesic regimen with opioids. Translational Medicine @ UniSa 2012;3(8):62-66en_US
dc.identifier.issn2239-9747en_US
dc.identifier.urihttp://hdl.handle.net/10556/627
dc.description.abstractPain is one of the most common and often most feared symptoms in patients with cancer. Ongoing or progressive pain is physically debilitating and has a marked impact on quality of life. During their illness, at least 70% of patients will experience pain sufficiently severe to require chronic opioid treatment. Moreover, Breakthrough Pain (BTP) consists in transitory exacerbations of pain that occurs on a background of otherwise stable pain in a patient receiving chronic opioid therapy. An inadequate baseline therapy with opioids can be one of the causes of BTP. We will examine the molecular issues that influence the response of patients to opioids. Finally, we will discuss about the importance of individualizing therapy.en_US
dc.format.extentP. 62-66en_US
dc.language.isoenen_US
dc.sourceUniSa. Sistema Bibliotecario di Ateneoen_US
dc.subjectBreakthrough Painen_US
dc.subjectμ-receptoren_US
dc.subjectPolimorphismsen_US
dc.titleBreakthrough pain: the importance of baseline analgesic regimen with opioidsen_US
dc.typeArticleen_US
 Find Full text

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record